Wadih Jordan Net Worth

Wadih Jordan biography

Wadih Jordan serves as Independent Director of the Company. Mr. Jordan was most recently the founder and President of NearEast Enterprise, L.L.C. from 2011 to April 2015, a company that marketed pharmaceuticals in Near East markets, including Lebanon, Turkey, Saudi Arabia, Egypt, and the Gulf countries. From 1995 to 2011, Mr. Jordan served as President of NearEast Pharma LLC, a company that provided pharmaceutical, biotechnology and equipment for pharmaceutical industries to the Near East and Middle East markets. From 1993 to 1995, Mr. Jordan served as a Vice President of Cyanamid International, a research-based life sciences company, and from 1976 to 1993, Mr. Jordan served as a Managing Director within Cyanamid International. From December 2003 to December 2015, Mr. Jordan was a trustee of the Board of Directors of the Lebanese American University, located in Beirut, Lebanon, and incorporated under the Board of Regents in New York State. Mr. Jordan received a bachelor’s degree in agriculture at the American University of Beirut, Lebanon, and a certificate in international business from Columbia University. Mr. Jordan brings to our Board years of expertise in both the biotechnology/pharmaceutical and international arenas.

What is the salary of Wadih Jordan?

As the Independent Director of Agenus Inc, the total compensation of Wadih Jordan at Agenus Inc is 457,141$. There are 9 executives at Agenus Inc getting paid more, with Garo Armen having the highest compensation of 9,937,040$.

How old is Wadih Jordan?

Wadih Jordan is 85, he's been the Independent Director of Agenus Inc since 2003. There are no older and 13 younger executives at Agenus Inc.

What's Wadih Jordan's mailing address?

Wadih's mailing address filed with the SEC is C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON, MA, 02421.

Insiders trading at Agenus Inc

Over the last 23 years, insiders at Agenus Inc have traded over 24,466,328$ worth of Agenus Inc stock and bought 13,248,226 units worth 63,837,873$ . The most active insiders traders include Associates Gp Llcqvt Fund V...、Noubar Afeyan、Corp Incyte. On average, Agenus Inc executives and independent directors trade stock every 99 days with the average trade being worth of 2,230,885$. The most recent stock trade was executed by Garo H Armen on 15 February 2024, trading 500,000 units of AGEN stock currently worth 325,000$.

What does Agenus Inc do?

agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody

Agenus Inc executives and stock owners

Agenus Inc executives and other stock owners filed with the SEC include:

• Garo Armen,
  Chairman of the Board, Chief Executive Officer, Co-Founder
• Jennifer Buell,
  President, Chief Operating Officer
• Evan Kearns,
  Chief Compliance Officer, Vice President, General Counsel, Corporate Secretary
• Dr. Garo H. Armen,
  Founder, Exec. Chairman & CEO
• Dr. Garo H. Armen Ph.D.,
  Founder, Exec. Chairman & CEO
• Brian Corvese,
  Independent Director
• Timothy Wright,
  Lead Independent Director
• Ulf Wiinberg,
  Independent Director
• Christine Klaskin,
  Chief Accounting Officer, Vice President - Finance
• Wadih Jordan,
  Independent Director
• Allison Jeynes-Ellis,
  Independent Director
• Christine M. Klaskin,
  VP of Fin., Principal Financial Officer & Principal Accounting Officer
• Susan Hirsch,
  Director
• Paul Clark,
  Director
• Donald Vidic,
  Vice President - Head of Commercial
• Dr. Steven J. O'Day M.D., Ph.D.,
  Chief Medical Officer
• Julie DeSander,
  Chief Bus. Officer
• Dr. Marcus Antonius van Dijk Ph.D.,
  Chief Technology Officer
• Alfred Dadson,
  Chief Manufacturing Officer
• Dhan Chand,
  Scientific Director & Head of Drug Discovery
• Paulo Moreira,
  Global Head of Clinical Operations
• John Castle,
  Head of Translational Medicine & Bioinformatics
• Adam Krauss J.D.,
  Chief Legal & Compliance Officer
• Regina Grebla Ph.D.,
  VP of Investor Relations & Communications
• Dr. Marc van Dijk Ph.D.,
  Chief Technology Officer
• Shahzad Malik,
  Director
• Jean Marie Cuillerot,
  Chief Medical Officer
• Corp Incyte,
  10% owner
• Charles Evan Ballantyne,
  CFO
• Robert Benjamin Stein,
  Chief Scientific Officer
• Shalini Sharp,
  Director
• Alex Duncan,
  Chief Technology Officer
• Eisen Margaret,
  Director
• Ozer Baysal,
  Chief Business Officer
• Associates Gp Llcqvt Fund V...,
  
• Tom Dechaene,
  Director
• Timothy G Rothwell,
  Director
• John Hatsopoulos,
  Director
• Hyam Levitsky,
  Director
• Kerry Wentworth,
  VP, Reg Affairs & Clinical Ops
• Karen Valentine,
  Chief Legal Officer
• Alastair Jj Wood,
  Director
• Pramod Srivastava,
  Director
• Roman Chicz,
  SVP Research & Preclinical Dev
• Bruce Leicher,
  VP, General Counsel
• Russell Herndon,
  Pres, Commercial Operations
• Gamil De Chadarevian,
  Director
• Mark Kessel,
  Director
• Peter J. Thornton,
  CFO & Sr. VP
• Frank V Iii Atlee,
  Director
• Noubar Afeyan,
  Director
• Jeff D Clark,
  Chief Financial Officer
• Renu Gupta,
  Sr. Vice President
• Neal Gordon,
  SrVP, Manufacturing Operations
• Christian Cortis,
  Chief Strategy Officer
• Thomas L Harrison,
  
• Adam Krauss,
  Chief Legal Officer
• Steven J O'day,
  Chief Medical Officer